Abstract
Currently, three strategies for primary treatment of advanced non-small cell lung cancer (NSCLC) with EGFR gene mutations are being investigated: epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) monotherapy, EGFR-TKI + vascular endothelial growth factor (VEGF) inhibitor combination, and EGFR-TKI + cytotoxic anticancer agent combination ( Tables 1,2 ).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
